Provenance
Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.
Planned Review
Following the December 2025 launch of revised UKMEC guidelines from CoSRH, all reproductive health PGD/protocols are being reviewed to ensure they reflect the updated UKMEC.
There are no expected changes in the content of this PGD template.
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).
More reproductive health PGD templates
- Combined hormonal contraceptive transdermal patch
- Combined hormonal contraceptive vaginal ring
- Combined oral hormonal contraceptive (COC) in reproductive health
- Ulipristal acetate 30mg tablets for emergency contraception
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Medroxyprogesterone acetate (SC-DMPA) injection for contraception
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Medroxyprogesterone acetate (DMPA) IM injection for contraception
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Lidocaine injection for subdermal etonogestrel in contraception
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Copper Intrauterine Device (Cu-IUD)
All PGD templates
National PGD, protocol and written instructions templates
Update history
- V2.3 PGD template removed as expired. Explanatory wording regarding versions of PGD template removed.
- Revised template due to minor clarifications following feedback.
- Planned update detail added
- Republished
- Version 3 published and explanatory wording added. Page reviewed
- Information added regarding name change of FSRH to CoSRH
- Version 2.3 published. Added statement to reflect new FSRH advice on desogestrel and risk of meningioma. Updated references.
- Detail of planned update added following new FSRH advice
- Details of a planned update to this template added
- Updated template published (changes detailed within document)
- Updated template published
- Title, URL and summary amended.
- Version 1 removed as expiring end March '23
- Version 2.0 PGD template added
- Published